Literature DB >> 21432295

Genetic polymorphisms ofCYP2A6 andCYP2E1 with tobacco smoking is not associated with risk of urothelial cancer.

Hiromasa Tsukino1, Yoshiki Kuroda, Hiroyuki Nakao, Hirohisa Imai, Yukio Osada, Hisato Inatomi, Kyoko Kitagawa, Toshihiro Kawamoto, Takahiko Katoh.   

Abstract

OBJECTIVES: To elucidate the association between genetic polymorphisms ofCYP2a6 andCYP2E1 and urothelial cancer susceptibility.
METHODS: A total of 137 Japanese patients with urothelial cancer and 217 Japanese healthy controls, frequency-matched for age and gender, were selected. The polymorphisms ofCYP2A6 andCYP2E1 were analyzed by PCR-RFLP, and cigarette smoking histories were obtained through interviews
RESULTS: The frequency ofCYP2A6 homozygote deletion genotype was 2.9% in the patients, compared with 3.2% in the controls (OR=0.84, 95% CI 0.24-2.96). The frequencies ofCYP2E1 C1/c2 andC2/c2 were 27.7% and 4.4% in the patients, compared with 35.5% and 6.0% in the controls (OR=0.68, 95% CI 0.42-1.09, OR=0.67, 95% CI 0.24-1.84, respectively). No statistically significant differences were observed when theCYP2A6 homozygote deletion genotype and theCYP2E1 genotypes were examined relative to smoking status.
CONCLUSIONS: Our data indicate that neither a relationship between genetically impaired nitrosamine metabolism and tobacco-smoking consumption, nor urothelial cancer risk related to theCYP2A6 deletion genotype andCYP2E1 Rsa I genotype was found in Japanese population.

Entities:  

Keywords:  CYP2A6; CYP2E1; Japanese; smoking; urothelial cancer

Year:  2002        PMID: 21432295      PMCID: PMC2723495          DOI: 10.1265/ehpm.2002.129

Source DB:  PubMed          Journal:  Environ Health Prev Med        ISSN: 1342-078X            Impact factor:   3.674


  7 in total

1.  Evidence for cytochrome P450 2A6 and 3A4 as major catalysts for N'-nitrosonornicotine alpha-hydroxylation by human liver microsomes.

Authors:  C J Patten; T J Smith; M J Friesen; R E Tynes; C S Yang; S E Murphy
Journal:  Carcinogenesis       Date:  1997-08       Impact factor: 4.944

2.  PstI and RsaI RFLPs in complete linkage disequilibrium at the CYP2E gene.

Authors:  J Watanabe; S Hayashi; K Nakachi; K Imai; Y Suda; T Sekine; K Kawajiri
Journal:  Nucleic Acids Res       Date:  1990-12-11       Impact factor: 16.971

3.  A novel single nucleotide polymorphism altering stability and activity of CYP2a6.

Authors:  N Ariyoshi; Y Sawamura ; T Kamataki
Journal:  Biochem Biophys Res Commun       Date:  2001-03-02       Impact factor: 3.575

4.  Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population.

Authors:  M Oscarson; R A McLellan; H Gullstén; Q Y Yue; M A Lang; M L Bernal; B Sinues; A Hirvonen; H Raunio; O Pelkonen; M Ingelman-Sundberg
Journal:  FEBS Lett       Date:  1999-04-01       Impact factor: 4.124

5.  The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP.

Authors:  K Kitagawa; N Kunugita; T Katoh; M Yang; T Kawamoto
Journal:  Biochem Biophys Res Commun       Date:  1999-08-19       Impact factor: 3.575

6.  High variability of nitrosamine metabolism among individuals: role of cytochromes P450 2A6 and 2E1 in the dealkylation of N-nitrosodimethylamine and N-nitrosodiethylamine in mice and humans.

Authors:  A M Camus; O Geneste; P Honkakoski; J C Béréziat; C J Henderson; C R Wolf; H Bartsch; M A Lang
Journal:  Mol Carcinog       Date:  1993       Impact factor: 4.784

7.  Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human lung and liver microsomes and cytochromes P-450 expressed in hepatoma cells.

Authors:  T J Smith; Z Guo; F J Gonzalez; F P Guengerich; G D Stoner; C S Yang
Journal:  Cancer Res       Date:  1992-04-01       Impact factor: 12.701

  7 in total
  1 in total

1.  Association between CYP2E1 genetic polymorphisms and urinary cancer risk: a meta-analysis.

Authors:  Zhiqing Fang; Yun Wu; Ning Zhang
Journal:  Oncotarget       Date:  2017-09-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.